1. Home
  2. CRSP vs JXN Comparison

CRSP vs JXN Comparison

Compare CRSP & JXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • JXN
  • Stock Information
  • Founded
  • CRSP 2013
  • JXN 1961
  • Country
  • CRSP Switzerland
  • JXN United States
  • Employees
  • CRSP N/A
  • JXN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • JXN Life Insurance
  • Sector
  • CRSP Health Care
  • JXN Finance
  • Exchange
  • CRSP Nasdaq
  • JXN Nasdaq
  • Market Cap
  • CRSP 5.6B
  • JXN 6.5B
  • IPO Year
  • CRSP 2016
  • JXN N/A
  • Fundamental
  • Price
  • CRSP $52.57
  • JXN $94.38
  • Analyst Decision
  • CRSP Buy
  • JXN Hold
  • Analyst Count
  • CRSP 19
  • JXN 5
  • Target Price
  • CRSP $71.94
  • JXN $109.80
  • AVG Volume (30 Days)
  • CRSP 2.5M
  • JXN 520.8K
  • Earning Date
  • CRSP 11-10-2025
  • JXN 11-04-2025
  • Dividend Yield
  • CRSP N/A
  • JXN 3.39%
  • EPS Growth
  • CRSP N/A
  • JXN N/A
  • EPS
  • CRSP N/A
  • JXN 7.31
  • Revenue
  • CRSP $38,337,000.00
  • JXN $4,997,000,000.00
  • Revenue This Year
  • CRSP N/A
  • JXN $116.66
  • Revenue Next Year
  • CRSP $391.94
  • JXN $5.25
  • P/E Ratio
  • CRSP N/A
  • JXN $12.93
  • Revenue Growth
  • CRSP N/A
  • JXN 25.33
  • 52 Week Low
  • CRSP $30.04
  • JXN $64.70
  • 52 Week High
  • CRSP $78.48
  • JXN $108.35
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.88
  • JXN 43.80
  • Support Level
  • CRSP $52.42
  • JXN $92.76
  • Resistance Level
  • CRSP $58.48
  • JXN $96.37
  • Average True Range (ATR)
  • CRSP 3.56
  • JXN 3.19
  • MACD
  • CRSP -1.14
  • JXN -0.34
  • Stochastic Oscillator
  • CRSP 21.64
  • JXN 36.72

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About JXN Jackson Financial Inc.

Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail product offerings are comprised of annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. The company manages its business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments. The company generates the majority of its revenue from the Retail Annuities segment, which offers a variety of retirement income and savings products of variable annuities, registered index-linked annuities ("RILA"), fixed index annuities, fixed annuities, and payout annuities.

Share on Social Networks: